GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

Rhea-AI Summary

GlycoMimetics CEO to participate in fireside chat at Jefferies Healthcare Conference

Positive

• GlycoMimetics CEO, Harout Semerjian, will participate in a fireside chat at the Jefferies Healthcare Conference on June 7, 2023 at 4:00 p.m. ET

Negative

• None.

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023 at 4:00 p.m. ET.

A live webcast of the fireside chat will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations. An archived recording will be available for 30 days following the event.

About GlycoMimetics, Inc.

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases with high unmet needs. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition and its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates, with the goal of developing transformative therapies for diseases with high unmet need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of and data from clinical trials, planned or potential clinical development, regulatory interactions and submissions, the commercialization and potential benefits and impact of the Company’s drug candidates, and the Company’s expected cash runway. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2022, its Quarterly Report on Form 10-Q filed with the SEC on November 9, 2022, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005094/en/

Investors:

Argot Partners

Leo Vartorella/Collin Beloin

212-600-1902

Glycomimetics@argotpartners.com

Source: GlycoMimetics, Inc.

When and where will the fireside chat take place?

The fireside chat will take place at the Jefferies Healthcare Conference in New York, NY on June 7, 2023 at 4:00 p.m. ET.

Will the fireside chat be available for viewing online?

Yes, a live webcast of the fireside chat will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations.

How long will the recording of the fireside chat be available?

The archived recording of the fireside chat will be available for 30 days following the event.